ArticleNature protocols2013
Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.
Article in Nature protocols, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- PD-L1/TIGIT bispecific antibody showed survival advantage in animal model.Clinical and translational medicine · 2022Article
- Developing of specific monoclonal recombinant antibody fused to alkaline phosphatase (AP) for one-step detection of fig mosaic virus.3 Biotech · 2022Article
- Article
- TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.Oncoimmunology · 2020Article
- Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins.Journal of immunological methods · 2019Article
- Engineering a single-chain antibody against Trypanosoma cruzi metacyclic trypomastigotes to block cell invasion.PloS one · 2019Article
- Transient expression of human antibodies in mammalian cells.Nature protocols · 2018Article
- Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer.Scientific reports · 2017Article
- Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease.Biochemistry and biophysics reports · 2016Article
- Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses.Cell host & microbe · 2015Article
- Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.Journal of virology · 2015Article
- Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.Molecular & cellular proteomics : MCP · 2015Article
- Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.Toxins · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This protocol describes the design and development of recombinant monovalent antigen-binding molecules derived from monoclonal antibodies through rapid identification and cloning of the functional variable heavy (VH) and variable light (VL) genes and the design and cloning of a synthetic DNA sequence optimized for expression in recombinant bacteria. Typically, monoclonal antibodies are obtained from mouse hybridomas, which most often result from the fusion of B lymphocytes from immunized mice with murine myeloma cells. The protocol described here has previously been exploited for the successful development of multiple antibody-based molecules targeting a wide range of biomolecular targets. The protocol is accessible for research groups who may not be specialized in this area, and should permit the straightforward reverse engineering of functional, recombinant antigen-binding molecules from hybridoma cells secreting functional IgGs within 50 working days. Furthermore, convenient strategies for purification of antibody fragments are described.
Indexed as
Identifiers
23680984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.